Necrotizing enterocolitis: pathophysiology, platelet-activating factor, and probiotics.

Michael S Caplan, Brandy L Frost

Journal: Seminars in pediatric surgery 2013;22(2):88-93

PMID: 23611612

Full Text on Elsevier Science View on PubMed

Abstract

Although smaller and younger preterm neonates can now survive long term due to advances in neonatal medicine, necrotizing enterocolitis (NEC) continues to plague the clinicians caring for these tiny patients. Research studies have contributed to our understanding of this complex disease, including the role of platelet-activating factor (PAF), but preventative and treatment strategies remain limited. One promising preventative measure in recent years has been enteral supplementation of probiotics, but concerns remain regarding the optimal use of these organisms, and safe administration must be assured. This chapter reviews NEC pathophysiology, including the role of PAF, as well as literature on the use of probiotics in the preterm infant.

Address: Department of Pediatrics, NorthShore University HealthSystem, Pritzker School of Medicine, University of Chicago, 2650 Ridge Ave, Walgreen Building, Suite 1505, Evanston, Illinois, USA. [email protected]

DOI: 10.1053/j.sempedsurg.2013.01.005

Link outs

Free resources

Medical:

https://medlineplus.gov/prematurebabies.html

Other Literature Sources:

https://scite.ai/reports/23611612

Subscription / membership required

Full Text Sources:

MeSH Terms: Biomarkers, Enterocolitis, Necrotizing, Humans, Infant, Newborn, Infant, Premature, Infant, Premature, Diseases, Platelet Activating Factor, Probiotics, Randomized Controlled Trials as Topic, Treatment Outcome